Material Weakness (removed) — Previously disclosed material weaknesses in internal controls over financial reporting were fully remediated as of December 31, 2024 and no longer appear in current filing.

NASDAQ: DNTH Dianthus Therapeutics, Inc. /DE/ 10-K

Dianthus reports positive Phase 2 gMG data, early CIDP GO, in-licenses DNTH212; loss doubles to $162M

Filed March 9, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 11, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade DNTH commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 5, 2026 6:36 AM